Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving sorafenib together with gemcitabine works in
treating patients with recurrent or refractory ovarian cancer or primary peritoneal cancer.
Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their
growth and by stopping blood flow to the tumor. Drugs used in chemotherapy, such as
gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or
die. Giving sorafenib with gemcitabine may kill more tumor cells.